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Summary of doctor's thesis review results: 
 
The usefulness of exchanged protein directly activated by cAMP (Epac)1-inhibiting 
therapy for prevention of atrial and ventricular arrhythmias in mice 
 
Epac (exchanged protein directly activated by cAMP) 1 阻害療法の，心房性，心室
性不整脈予防における有用性の検討） 
 
Activation of the β-adrenergic receptor (β-AR) mediated pathway is one of the 
causes of arrhythmia. It has been suggested that protein directly activated by cAMP 
(Epac), one of the downstream signaling molecules of β-AR, may be an effective target 
for the treatment of arrhythmia. In this study, we examined the roles of Epac1 in the 
development of arrhythmias. In addition, we examined the usefulness of CE3F4, an 
Epac1-selective inhibitor, in the treatment of the arrhythmias in mice.  
In Epac1 knockout (Epac1-KO) mice, the duration of atrial fibrillation (AF) was 
shorter than in wild-type mice. In calsequestrin2 knockout (Casq2-KO) mice, Epac1 
deficiency resulted in a reduction of ventricular arrhythmia. In both atrial and 
ventricular myocytes, the sympathetic activation-induced sarcoplasmic reticulum (SR) 
Ca2+ leak and spontaneous SR Ca2+ release (SCR) were attenuated in Epac1-KO mice.  
Further, the CE3F4 shortens the duration of the pacing-induced AF. Moreover, 
CE3F4 treatment reduced the incidence of sympathetic activation-induced ventricular 
arrhythmias. In addition, the sympathetic activation-induced SR Ca2+ leak and rate of 
SCR were attenuated by CE3F4 in mouse cardiomyocytes.  
Importantly, cardiac function was not significantly affected by a dosage of 
CE3F4 sufficient to exert the anti-arrhythmic effects. 
These findings indicated that Epac1 was involved in the development of atrial 
and ventricular arrhythmias. CE3F4 prevented atrial and ventricular arrhythmias 
without suppressing cardiac functions in mice. Epac1-inhibiting therapy may be a 






The following questions and answers were made after the explanation of 
the summary of the above thesis for the review． 
 
Firstly, the following question and comment were made by Assoc. Prof. Dr. Toshiyuki 
Ishikawa       
1. Is there any report regarding the toxicity of CE3F4? 
2. During the sympathetic activation, why only the inhibition of Epac1 pathway 
blocked the Ca2+ leakage? 
3. What will happen if both the PKA and Epac1 pathways are blocked? 
 
For these questions, we obtained the following answers. 
1. There is no any report on the toxicity of CE3F4 so far. In fact, no report of CE3F4 in 
vivo study was yet done.  
2. Our result showed that Epac1 pathway blockage is enough to suppress Ca2+ 
leakage caused by sympathetic effect. Moreover, PKA pathway may be involve in 
the cardiac function rather than Ca2+ leakage.  
3. If we block both Epac1 and PKA, we can assume that the result will be similar to 
β-AR blocker.  
 
 
Next, the following questions and comments were made by Assoc. Prof. Dr. Shinichi 
Suzuki  
1. How did you decide 3mg/kg of metoprolol? 
2. Have you tried the low concentration of metoprolol? 
3. What do you think about the side effects of CE3F4? How was the condition of mice 
with CE3F4 infusion?  
 
For these questions, we obtained the following answers. 
1. Based on the previous study, we have decided 3mg/kg of metoprolol 
concentration. In a previous paper, 3mg/kg of metoprolol was used to observe the 
cardiac function.  
2. We have used 0.3mg/kg of metoprolol which is enough to decrease the cardiac 
function but didn’t suppress the arrhythmia. 
3. The side effects of CE3F4 may relate to the specific site where the expression of 
Epac1 is present. Dysfunction of Epac1 may seem to contribute to Alzheimer’s 
disease, schizophrenia, pulmonary hypertension, asthma, diabetes etc. The 
conditions of mice seem normal with CE3F4 infusion. 
 
At the end, the following questions and comments were made by the Chief Judge 
Prof. Dr. Yoshio Goshima 
1. Are there any different phosphorylation sites of RYR2 for PKA and CaMKII 
pathways? 
2. Why selective inhibition of Epac1 doesn’t affect the cardiac function?  
3. Have you ever look into the PKA inhibitor and compare with Epac1 inhibitor? 
4. What do you think about the clinical application of Epac1 inhibitor?  
 
For these questions, we obtained the following answers. 
1. PKA phosphorylates RyR2 at Serine2808, whereas Epac1 phosphorylates RyR2 at 
Serine2814 site through the CaMKII.  
2. The PKA pathway, through the β-AR activation, maintains the cardiac function. 
Whereas the Epac1 pathway may not play the central role in the cardiac function. 
Hence, the biological response of Epac1 and PKA pathway may be different.  
3. I have not used PKA inhibitor in our study. However, H89 is used as a PKA inhibitor 
in some papers. In our study Epac1 is sufficient to suppress the sympathetic 
activation induced Ca2+ leak to the baseline. Further, if we use PKA inhibitor which 
blocks the catalytic region, it may cause lethal action.  
4. Based on the various pathophysiological states of cardiac diseases, we can decide 
whether we can use different class of β-AR blocker or Epac1 inhibitor. The Epac1 is 
responsible for rhythm control rather that rate control.  
 
In addition to the above, we got an appropriate response to the various questions of 
the judges. The report may provide a basis for development of more useful and secure 
treatment for arrhythmias. After successful oral defense presentation, we all examiners 
unanimously recommend that the candidate should be awarded the degree of Doctor 
of Philosophy (PhD). 
 
上記のように、本研究は、マウスモデルにおいて Epac1 の阻害が、心房・心室性
不整脈を抑制する効果を示すものであり、当該領域の学術研究に資するもので
ある。本審査では、申請者はその背景や課題、今後の展望について適確に把握
し、自らの研究に取り組んできたことがうかがえた。よって本審査委員会は、
学位、医学博士に値すると判断した。 
 
